Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.
A candidate to be President Donald Trump's science advisor supports limiting federal researchers' ability to discuss their findings, the Guardian reports.
Vox reports that recent policy shifts have led to confusion and uncertainty at the US Food and Drug Administration.
The Wall Street Journal reports that Rep. Tom Price, the pick to lead the Department of Health and Human Services, bought stock in a pharma firm at a special price.
The US immigration ban is already having an effect on US science, the New Scientist says.
Stat News writes that the new executive order on government regulations could affect the 21st Century Cures Act.
Stat News reports that Joseph Gulfo is another contender for FDA commissioner.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.
Technology Review points out that a new US presidential science advisor hasn't been selected.
In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.
Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.
Researchers are using gene editing to develop more robust livestock and crops, AFP reports.